Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
This study describes lysostaphin's effect against methicillin-sensitive Staphylococcus aureus in suckling rats. Standard techniques determined minimal inhibitory and bactericidal concentrations, pharmacokinetics, and efficacy. The numbers of surviving rats after vancomycin, oxacillin, and lysostaphin treatment were comparable and were different from that of controls (P < 0.00001). Lysostaphin appears effective in the treatment of neonatal S. aureus infection.
Oluola
Okunola
O
Baylor College of Medicine and Perinatal Center, Texas Children's Hospital, 6621 Fannin St., FC830.17, Houston, TX 77030-2799, USA.
Kong
Lingkun
L
Fein
Mindy
M
Weisman
Leonard E
LE
D000818:Animals; D000833:Animals, Suckling; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D007231:Infant, Newborn; D008248:Lysostaphin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality*; D013211:Staphylococcus aureus / Q000145:classification / Q000187:drug effects*; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D008248:Lysostaphin